Clinical Trial Update: Study of Efalizumab Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular Degeneration [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating the combination of efalizumab and intravitreal ranibizumab for age-related macular degeneration was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Choroidal Neovascularization

Drugs mentioned

• Lucentis (ranibizumab)
• Raptiva (efalizumab)

Snippet

Sponsor: Vitreous -Retina- Macula Consultants of New York | Conditions: Age Related Macular Degeneration, AMD | Phase 1 | Status: WITHDRAWN